Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Ammonia Solution, Strong. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL1723530 | 1.00 | — | — | |
| Ammonia Solution, Strong SCHEMBL524152 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL9763208 | 0.92 | — | — | |
| SCHEMBL45362 | 0.92 | — | — | |
| SCHEMBL12111341 | 0.92 | — | — | |
| SCHEMBL12111337 | 0.92 | — | — | |
| SCHEMBL27702029 | 0.88 | — | — | |
| SCHEMBL27769735 | 0.88 | — | — | |
| SCHEMBL27348093 | 0.88 | — | — | |
| Phosphine SCHEMBL28154723 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3214082-B1 | PROCESS FOR MANUFACTURING PYRIMIDINE SULFAMIDE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2021-11-10 | — | — | EP | claimed |
| EP-3105220-B1 | PROCESS FOR MANUFACTURING PYRIMIDINE SULFAMIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-07-01 | — | — | EP | claimed |
| US-9938244-B2 | Process for manufacturing pyrimidine sulfamide derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-10 | — | — | US | claimed |
| EP-3214082-A1 | PROCESS FOR MANUFACTURING PYRIMIDINE SULFAMIDE DERIVATIVES | Actelion Pharmaceuticals Ltd (CH) | 2017-09-06 | — | — | EP | claimed |
| US-20160368882-A1 | PROCESS FOR MANUFACTURING PYRIMIDINE SULFAMIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-12-22 | — | — | US | claimed |
| CN-105992762-A | Process for the manufacture of pyrimidine sulfonamide derivatives | 埃科特莱茵药品有限公司 | 2016-10-05 | — | — | CN | claimed |
| EP-3214082-B1 | PROCESS FOR MANUFACTURING PYRIMIDINE SULFAMIDE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2021-11-10 | — | — | EP | disclosed |
| EP-3105220-B1 | PROCESS FOR MANUFACTURING PYRIMIDINE SULFAMIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-07-01 | — | — | EP | disclosed |
| CN-105992762-B | Process for the manufacture of pyrimidine sulfonamide derivatives | 爱杜西亚药品有限公司 | 2019-04-16 | — | — | CN | disclosed |
| US-9938244-B2 | Process for manufacturing pyrimidine sulfamide derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-10 | — | — | US | disclosed |
| CN-107162988-A | The method for manufacturing pyrimidine sulphonamide derivatives | 埃科特莱茵药品有限公司 | 2017-09-15 | — | — | CN | disclosed |
| EP-3214082-A1 | PROCESS FOR MANUFACTURING PYRIMIDINE SULFAMIDE DERIVATIVES | Actelion Pharmaceuticals Ltd (CH) | 2017-09-06 | — | — | EP | disclosed |
| US-20160368882-A1 | PROCESS FOR MANUFACTURING PYRIMIDINE SULFAMIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-12-22 | — | — | US | disclosed |
| CN-105992762-A | Process for the manufacture of pyrimidine sulfonamide derivatives | 埃科特莱茵药品有限公司 | 2016-10-05 | — | — | CN | disclosed |
| EP-2688866-A1 | TRPV1 ANTAGONISTS | AbbVie Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| WO-2012134943-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2012-10-04 | — | — | WO | disclosed |
| EP-0837063-A1 | 4-Aminoquinazoline derivatives | PFIZER INC. (US) | 1998-04-22 | — | — | EP | disclosed |